178 related articles for article (PubMed ID: 31799782)
1. Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial.
Paiman EHM; van Eyk HJ; van Aalst MMA; Bizino MB; van der Geest RJ; Westenberg JJM; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Rensen PCN; Smit JWA; Jazet IM; Lamb HJ
J Magn Reson Imaging; 2020 Jun; 51(6):1679-1688. PubMed ID: 31799782
[TBL] [Abstract][Full Text] [Related]
2. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
[TBL] [Abstract][Full Text] [Related]
3. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study.
Kumarathurai P; Sajadieh A; Anholm C; Kristiansen OP; Haugaard SB; Nielsen OW
Cardiovasc Diabetol; 2021 Jan; 20(1):12. PubMed ID: 33413428
[TBL] [Abstract][Full Text] [Related]
4. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW
Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988
[TBL] [Abstract][Full Text] [Related]
5. Phenotyping diabetic cardiomyopathy in Europeans and South Asians.
Paiman EHM; van Eyk HJ; Bizino MB; Dekkers IA; de Heer P; Smit JWA; Jazet IM; Lamb HJ
Cardiovasc Diabetol; 2019 Oct; 18(1):133. PubMed ID: 31604432
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients.
van Eyk HJ; Paiman EHM; Bizino MB; de Heer P; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Smit JWA; Lamb HJ; Rensen PCN; Jazet IM
Cardiovasc Diabetol; 2019 Jul; 18(1):87. PubMed ID: 31288820
[TBL] [Abstract][Full Text] [Related]
7. Late effects of pediatric hematopoietic stem cell transplantation on left ventricular function, aortic stiffness and myocardial tissue characteristics.
Paiman EHM; Louwerens M; Bresters D; Westenberg JJM; Tao Q; van der Geest RJ; Lankester AC; Roest AAW; Lamb HJ
J Cardiovasc Magn Reson; 2019 Jan; 21(1):6. PubMed ID: 30651110
[TBL] [Abstract][Full Text] [Related]
8. Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Bojer AS; Sørensen MH; Bjerre J; Gaede P; Vejlstrup N; Madsen PL
Diabetes Obes Metab; 2021 Oct; 23(10):2374-2384. PubMed ID: 34189832
[TBL] [Abstract][Full Text] [Related]
9. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
[TBL] [Abstract][Full Text] [Related]
10. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
Kumarathurai P; Anholm C; Nielsen OW; Kristiansen OP; Mølvig J; Madsbad S; Haugaard SB; Sajadieh A
Cardiovasc Diabetol; 2016 Jul; 15(1):105. PubMed ID: 27455835
[TBL] [Abstract][Full Text] [Related]
11. Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial.
Jørgensen PG; Jensen MT; Mensberg P; Storgaard H; Nyby S; Jensen JS; Knop FK; Vilsbøll T
Diabetes Obes Metab; 2017 Jul; 19(7):1040-1044. PubMed ID: 28188972
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction.
Hamad F; Elnour AA; Elamin A; Mohamed S; Yousif I; Don J; Abdi S; Al Amoodi A; Fathelrahman AI; Gnana K; Alanzi F; Abubakar AB; Magboul SM; Ahmed SA; Sadeq A
Curr Diabetes Rev; 2021; 17(3):280-292. PubMed ID: 32867644
[TBL] [Abstract][Full Text] [Related]
13. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
Jorsal A; Kistorp C; Holmager P; Tougaard RS; Nielsen R; Hänselmann A; Nilsson B; Møller JE; Hjort J; Rasmussen J; Boesgaard TW; Schou M; Videbaek L; Gustafsson I; Flyvbjerg A; Wiggers H; Tarnow L
Eur J Heart Fail; 2017 Jan; 19(1):69-77. PubMed ID: 27790809
[TBL] [Abstract][Full Text] [Related]
14. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials.
Xia W; Yu H; Lei X; Wen P
Medicine (Baltimore); 2024 Mar; 103(11):e37432. PubMed ID: 38489694
[TBL] [Abstract][Full Text] [Related]
15. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Margulies KB; Hernandez AF; Redfield MM; Givertz MM; Oliveira GH; Cole R; Mann DL; Whellan DJ; Kiernan MS; Felker GM; McNulty SE; Anstrom KJ; Shah MR; Braunwald E; Cappola TP;
JAMA; 2016 Aug; 316(5):500-8. PubMed ID: 27483064
[TBL] [Abstract][Full Text] [Related]
16. 4D flow MRI, cardiac function, and T
Geiger J; Rahsepar AA; Suwa K; Powell A; Ghasemiesfe A; Barker AJ; Collins JD; Carr JC; Markl M
J Magn Reson Imaging; 2018 Jul; 48(1):121-131. PubMed ID: 29206322
[TBL] [Abstract][Full Text] [Related]
17. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
[TBL] [Abstract][Full Text] [Related]
18. Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2).
Wägner AM; Miranda-Calderín G; Ugarte-Lopetegui MA; Marrero-Santiago H; Suárez-Castellano L; López-Madrazo MJ; Alberiche-Ruano MP; Abselam Ahmed N; Alemán C; Castellot-Martín A; Díez Del Pino A; Nóvoa-Mogollón FJ
Diabetes Metab; 2019 Jun; 45(3):268-275. PubMed ID: 30223083
[TBL] [Abstract][Full Text] [Related]
19. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Liakos A; Lambadiari V; Bargiota A; Kitsios K; Avramidis I; Kotsa K; Gerou S; Boura P; Tentolouris N; Dimitriadis G; Tsapas A
Diabetes Obes Metab; 2019 Mar; 21(3):517-524. PubMed ID: 30242948
[TBL] [Abstract][Full Text] [Related]
20. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
